poisar

Stocks · News reference

QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000

BenzingaPiero Cingari

Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on rival Lp(a) drug olpasiran.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolJosh Kohn-Lindquist

    Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons

    Major stock indices declined on September 8, 2026, as rising crude oil prices approaching $100/barrel and geopolitical tensions weighed on markets. The Dow fell 1.18%, S&P 500 dropped 0.58%, and Nasdaq declined 0.31%. Notable movers included Intel gaining 9% on pricing plans, Corning rising 7% on a Verizon fiber deal, while Amgen and Novartis fell sharply following a drug trial setback. Qualcomm signed a major AI chip deal with Amazon worth up to $60 billion.

  2. The Motley FoolStefon Walters

    1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond

    The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.